Next Article in Journal
Evaluation of a Routine Screening Program with Tuberculin Skin Testing on Rates of Detection of Latent Tuberculosis Infection and Prevention of Active Tuberculosis in Patients with Multiple Myeloma at a Canadian Cancer Centre
Previous Article in Journal
Preparing for the Renaissance: Treating Breast Cancer during the COVID-19 Pandemic and Planning for a Safe Re-Emergence to Routine Surgical Care within a Universal Health Care System
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 3
10.3747/co.27.5371
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series

by
I. Landego
1,
D. Hewitt
2,
I. Hibbert
3,
D. Dhaliwal
4,
W. Pieterse
5,
D. Grenier
4,
R. Wong
4,
J. Johnston
2,4 and
V. Banerji
2,4,*
1
Department of Internal Medicine, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
2
Research Institute of Oncology and Hematology, CancerCare Manitoba and the University of Manitoba, Winnipeg, MB, Canada
3
Department of Nursing, CancerCare Manitoba, Winnipeg, MB, Canada
4
Section of Hematology and Oncology, Rady College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
5
Russell Health Centre, Community Oncology Program, Winnipeg, MB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(3), 169-172; https://doi.org/10.3747/co.27.5371
Submission received: 10 March 2020 / Revised: 3 April 2020 / Accepted: 5 May 2020 / Published: 1 June 2020

Abstract

Chronic lymphocytic leukemia (cll) is the most common adult leukemia in the Western world. Unfortunately, affected patients are often immunosuppressed and at increased risk of infection and secondary malignancy. Previous meta-analysis has found that patients with cll have a risk of melanoma that is increased by a factor of 4 compared with the general population. Recent advances in the understanding of the PD receptor pathway have led to immunotherapies that target cancer cells. The use of PD-1 inhibitors is now considered first-line treatment for BRAF wild-type metastatic melanoma. Interestingly, early preclinical data suggest that inhibition of that pathway could also be used in the treatment of cll; however, recent clinical data did not support the effectiveness of that approach. In this case series, we highlight 2 cases in which patients with cll and concurrent malignant melanoma underwent treatment with PD-1 inhibitors and were found to experience reductions in their white blood cell counts without improvement in their hemoglobin. Those cases further illustrate that treatment of cll with PD-1 inhibitors is ineffective.
Keywords: immunotherapy; chronic lymphocytic leukemia; cll; melanoma immunotherapy; chronic lymphocytic leukemia; cll; melanoma

Share and Cite

MDPI and ACS Style

Landego, I.; Hewitt, D.; Hibbert, I.; Dhaliwal, D.; Pieterse, W.; Grenier, D.; Wong, R.; Johnston, J.; Banerji, V. PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series. Curr. Oncol. 2020, 27, 169-172. https://doi.org/10.3747/co.27.5371

AMA Style

Landego I, Hewitt D, Hibbert I, Dhaliwal D, Pieterse W, Grenier D, Wong R, Johnston J, Banerji V. PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series. Current Oncology. 2020; 27(3):169-172. https://doi.org/10.3747/co.27.5371

Chicago/Turabian Style

Landego, I., D. Hewitt, I. Hibbert, D. Dhaliwal, W. Pieterse, D. Grenier, R. Wong, J. Johnston, and V. Banerji. 2020. "PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series" Current Oncology 27, no. 3: 169-172. https://doi.org/10.3747/co.27.5371

APA Style

Landego, I., Hewitt, D., Hibbert, I., Dhaliwal, D., Pieterse, W., Grenier, D., Wong, R., Johnston, J., & Banerji, V. (2020). PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series. Current Oncology, 27(3), 169-172. https://doi.org/10.3747/co.27.5371

Article Metrics

Back to TopTop